PHBI – Pharmagreen Signs Supply Contract and Trade Marked Name Use of SierraSil(R) in Its’ Nutraceutical Formulations
CARSON CITY, NV / ACCESSWIRE / January 24, 2024 / Pharmagreen Biotech, Inc., (OTC PINK:PHBI), "Pharmagreen" or the "Company" is...
DNA
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that...
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).ZyVersa...
Everest Group recognizes Indegene as a Leader in Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024
Everest Group recognizes Indegene as a Leader in Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024 Everest Group recognizes...
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands Erasmus Medical Center Erasmus Medical Center OCALA, Fla., Jan....
Angle PLC Announces Potential Utility in Precision Oncology
REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGYPaper published in the journal "Current...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker...
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership...
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells...
Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040,...
SEQSTER Launches 1-Click Records™ for Healthcare & Life Sciences
Retrieve a Patient’s Longitudinal Health Record in Seconds to Confirm Study Eligibility & Query Population Cohorts via the Admin PortalSAN...
Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
Financing advances development of Prota's peanut allergy remission therapy in preparation for a Phase 3 clinical trialMELBOURNE, AUSTRALIA / ACCESSWIRE...
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences...
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated...
Medicenna Announces Appointment of New Auditor
TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage...
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
iStopMM team members Thorir Einarsson Long, Jon Thorir Oskarsson, and Sæmundur Rognvaldsson are 2023 ASH Abstract Achievement AwardeesSTUDIO CITY, Calif.,...
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...